ESC 365 - Newer P2Y12 inhibitors in a real-world setting: long-term outcomes from contemporary PCI with newer versus traditional dual antiplatelet regimes.

ESC Premium Access

Newer P2Y12 inhibitors in a real-world setting: long-term outcomes from contemporary PCI with newer versus traditional dual antiplatelet regimes.

Session: Antiplatelet therapy in PCI

Topic: Antiplatelet Drugs

Speaker: Doctor M. Mohamed (London, GB)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor Mohamed Mohamed

University College London, London (United Kingdom of Great Britain & Northern Ireland)

0 follower

4 more presentations in this session

Antiplatelet therapy - State of the art

Speaker: Professor B. Rocca (Casamassima, IT)

Association of plasma concentration of trimethylamine N-oxide and ADP-induced platelet reactivity after a loading dose of clopidogrel 600 mg in patients undergoing elective PCI

Speaker: Professor D. Trenk (Bad Krozingen, DE)

Meta-analysis of use of proton pump inhibitors with dual antiplatelet therapy after acute coronary syndrome

Speaker: Doctor E. Kaluski (Sayre, US)

The future of DAPT

Speaker: Professor R. Storey (Sheffield, GB)

Access the full session

Antiplatelet therapy in PCI

Speakers: Doctor M. Mohamed, Professor B. Rocca, Professor D. Trenk, Doctor E. Kaluski, Professor R. Storey

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources